Across TCGA pan-cancer cohorts, MFSD6L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFSD6L data layer compared with 24 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MFSD6L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MFSD6L expression acts as an unfavorable survival marker.
ACC, BLCA, and LIHC are the cancer types where MFSD6L Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.